Literature DB >> 8226430

Alterations of host response by a long-term treatment of roxithromycin.

E Kita1, M Sawaki, K Mikasa, K Hamada, S Takeuchi, K Maeda, N Narita.   

Abstract

Roxithromycin (10 mg/kg) was administered once-daily for seven or 28 days to mice intragastrically and its effects on cytokine synthesis were studied. Administration of roxithromycin for 28 days resulted in increased synthesis of interleukin (IL)-1 and tumour necrosis factor (TNF-alpha) production by macrophages, and the production of IL-2, IL-4 and interferon gamma by splenocytes. In contrast, 7 day administration of roxithromycin did not affect these parameters. Furthermore, clindamycin treatment did not significantly increase the capacity of host cells to produce cytokines, irrespective of the duration of treatment, when compared with the solvent control receiving 0.9% ethanol solution or the untreated controls. In addition, the supernatant of a 7 day culture of splenocytes with roxithromycin showed suppression of the production of TNF-alpha and prostaglandin E2 by mitogen-stimulated macrophages, and this suppressive activity was impaired by a monoclonal antibody to murine IL-4. Thus, this data suggests that roxithromycin may not only enhance the host defence system through increased cytokine synthesis by host cells, but also exhibit anti-inflammatory activity by including an anti-inflammatory cytokine, IL-4.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8226430     DOI: 10.1093/jac/32.2.285

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

Review 1.  Immunomodulating effects of antibiotics: literature review.

Authors:  B Van Vlem; R Vanholder; P De Paepe; D Vogelaers; S Ringoir
Journal:  Infection       Date:  1996 Jul-Aug       Impact factor: 3.553

2.  A macrolide antibiotic, roxithromycin, inhibits the growth of human myeloid leukemia HL60 cells by producing multinucleate cells.

Authors:  M Nagai; H Yamada; S Nakada; K Ochi; T Nemoto; S Takahara; S Hoshina; J Horiguchi-Yamada
Journal:  Mol Cell Biochem       Date:  1995-03-23       Impact factor: 3.396

3.  Topical azithromycin and clarithromycin inhibit acute and chronic skin inflammation in sensitized mice, with apparent selectivity for Th2-mediated processes in delayed-type hypersensitivity.

Authors:  Vanesa Ivetić Tkalčević; Snježana Cužić; Miroslava Dominis Kramarić; Michael J Parnham; Vesna Eraković Haber
Journal:  Inflammation       Date:  2012-02       Impact factor: 4.092

4.  Roxithromycin, clarithromycin, and azithromycin attenuate the injurious effects of bioactive phospholipids on human respiratory epithelium in vitro.

Authors:  C Feldman; R Anderson; A J Theron; G Ramafi; P J Cole; R Wilson
Journal:  Inflammation       Date:  1997-12       Impact factor: 4.092

5.  Infectious causes of chronic inflammatory diseases and cancer.

Authors:  G H Cassell
Journal:  Emerg Infect Dis       Date:  1998 Jul-Sep       Impact factor: 6.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.